Breaking News, Collaborations & Alliances

Glycovax Pharma, NRC, Montréal U, Partner to Develop Vax Against Pa Infections

Aims to design a vaccine capable of inducing an immune response with bactericidal activity against Pseudomonas aeruginosa.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

glycoconjugate vaccine against Pseudomonas aeruginosa (Pa) infections

Glycovax Pharma entered a strategic collaboration with the National Research Council of Canada (NRC) and the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa (Pa) infections. This project is funded by a $467,661 grant from the Government of Quebec as well as financial support from other partners. Pa is an opportunistic bacterium responsible for respiratory infections in humans. Highly prone to antibiotic resistance, Pa infections are a leading cause of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters